News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Deborah Doroshow, MD

Articles by Deborah Doroshow, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 28th 2023

Conclusion of the discussion and award presentation.

Optimal Approach for PD-L1 >50%

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Treatment for Borderline Resectable Patients With NSCLC

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Introduction of the Debate Between Jets v. Giants

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.